



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 31/70, 31/715	A2	(11) International Publication Number: WO 97/02829 (43) International Publication Date: 30 January 1997 (30.01.97)
(21) International Application Number: PCT/US96/11201 (22) International Filing Date: 2 July 1996 (02.07.96) (30) Priority Data: 60/001,036 11 July 1995 (11.07.95) US 08/653,084 11 June 1996 (11.06.96) US (71) Applicant: ABBOTT LABORATORIES [US/US]; CHAD 377/AP6D-2, One Abbott Park Road, Abbott Park, IL 60064-3500 (US). (72) Inventors: DOHNALEK, Margaret, Ione, Halpin; 1483 Buck Trail Lane, Worthington, OH 43085 (US). OSTROM, Karin, Margaret; 7788 Quarry Cliff Court, Reynoldsburg, OH 43068 (US). HILTY, Milo, Duane; 9984 S. Old State Road, Lewis Center, OH 43035 (US). (74) Agents: BRAINARD, Thomas, D.; Abbott Laboratories, Ross Products Division, Dept. 108140 DS/1, 625 Cleveland Avenue, Columbus, OH 43215 (US) et al.		(81) Designated States: AU, BR, CA, IL, JP, MX, NO, NZ, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>Without international search report and to be republished upon receipt of that report.</i>
(54) Title: USE OF INDIGESTIBLE OLIGOSACCHARIDES TO PREVENT AND TREAT DIARRHEA (57) Abstract <p>A method is provided for reducing the duration of diarrhea and recurrent episodes of diarrhea in humans by enterally administering indigestible oligosaccharides prophylactically. More specifically, the present invention relates to a method using indigestible oligosaccharides or fructooligosaccharides (FOS) to reduce the duration and recurrence of diarrhea in a human wherein between 0.5 grams and 5 grams of at least one FOS selected from the group consisting of l-kestose, nystose, and 1F-β-fructofuranosyl nystose is administered to said human per day. The indigestible oligosaccharides can be produced through enzymatic synthesis, chemical techniques or isolated from plant materials and are administered in the form of a nutritional product, candy, tablets, chewing gum, lozenges, milk, yogurts, fermented products and the like.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

USE OF INDIGESTIBLE OLIGOSACCHARIDES TO PREVENT AND/TREAT DIARRHEA

This application claims the benefit of U.S. Provisional Application No. 60/001,036, filed July 11, 1995

FIELD OF THE INVENTION

5 The present invention relates to a method for reducing the duration of diarrhea by enterally administering to humans indigestible oligosaccharides.

BACKGROUND OF THE INVENTION

Prevention of gastrointestinal infections in young children and in adults is a significant public health problem that has not been solved. Methods of prevention presently available are limited to practices that reduce transmission of infectious agents to susceptible individuals. Such methods include sewage treatment, provisions of clean
10 water, hand washing, and good personal hygiene. The development of effective vaccines to prevent colonization by enteric pathogens has been limited due to the large number of potential pathogens and because young children, who are at greatest risk, fail to develop long-lasting immunity. Individuals treated with antibiotics for infectious diseases may also
15 become colonized with antibiotic-resistant bacteria and may not respond to antibiotic treatment at a later time.

Fructooligosaccharides (FOS) are natural substances composed primarily of fructose molecules. They belong to a group of carbohydrates that occur in many different plants. FOS are indigestible oligosaccharides that pass through the small intestine without
20 being digested, reaching the large intestine where they are selectively fermented by certain microorganisms. As used in this application and the claims, the terms FOS and indigestible oligosaccharides are interchangeable. FOS can be utilized efficiently by lactobacilli and bifidobacteria, species of bacteria that are beneficial for human health (Hidaka et al.). Selective fermentation of FOS by bifidobacteria leads to an increase in the

presence of these bacteria and to the production of acetic acid and lactic acid as fermentation end products, resulting in a lower pH in the digestive tract and providing a means to prevent the overgrowth of harmful bacterial like *Escherichia coli*, *Clostridium perfringens* and *Clostridium difficile*. (Hidaka et al., "Fructooligosaccharides: Enzymatic Preparation and Biofunctions", *Journal of Carbohydrate Chemistry* 10(4): 509-522, 1991). Fermentation of FOS can also lead to an increase in the presence of short chain fatty acids and the suppression of undesirable microorganisms such as *Clostridium perfringens*, *C. difficile*, or *E. coli* and the toxins they produce (Hidaka et al. "Fructooligosaccharides: Enzymatic Preparation and Biofunctions", *Journal of Carbohydrate Chemistry* 10(4): 509-522, 1991). Indigestible oligosaccharides such as FOS can be added to a nutritional product to create an environment in the gastrointestinal tract that is not conducive to the growth of microbial pathogens. Such a nutritional product can also be useful in the prevention of diarrhea caused by these pathogens.

Indigestible Oligosaccharides

"Indigestible oligosaccharides" refers to a small carbohydrate moiety that is resistant to endogenous digestion in the human upper digestive tract. Fructooligosaccharides (FOS) are indigestible oligosaccharides that are members of the inulin subclass of fructosans, polymers composed of fructose residues. FOS are sometimes characterized by their degree of polymerization. Degree of polymerization (DP) means the number of covalent bonds between the monosaccharide units in the polymer. For example, the tetramer nystose is composed of three fructose monomers bound to glucose (or sucrose plus two fructose units) and has a DP of 3. Using this nomenclature, sucrose is GF₁ (glucose plus fructose). Specifically, inulins are glucofructosans, carbohydrate polymers consisting of a chain of fructose residues linked by (2→1)-β-glycosidic bonds and usually having a single D-glycosyl residue lined (1→2)-α-to the first fructose molecule.

Fructooligosaccharides (FOS) can be produced enzymatically through chemical techniques or by extraction from natural substances. FOS occur in nature in many kinds of plants, including onions, garlic, shallots, artichokes, wheat, rye, bananas, asparagus and tomatoes, that are commonly part of a human diet (Speights et al., "Fructooligosaccharides

- A Low Caloric Bulking Agent And More From Sucrose", *Carbohydrates in Industrial Synthesis*, ed. M.A. Clarke, Proceedings of the Symposium of the Division of Carbohydrate Chemistry of the American Chemical Society, 1992). Another natural source of FOS is the chicory root. FOS can also be synthesized from sucrose through the use of transfructosylating enzymes. Treatment of sucrose with the transfructosylating enzyme from *Aspergillus niger* results in a mixture of fructooligosaccharides containing 2, 3 or 4 fructose residues, designated respectively: 1-kestose or GF₂ in which one molecule of fructose is bound to sucrose; nystose or GF₃ in which two molecules of fructose are bound to sucrose; and 1^F-β-fructofuranosyl nystose or GF₄ in which three molecules of fructose are bound to sucrose.

An enzymatic method of producing FOS industrially is taught in U.S. Patent No. 4,681,771 to Adachi et al. that comprises reacting sucrose in the presence of a fructosyltransferase (enzyme) to obtain GF₂, GF₃, GF₄ and GF₅. The source for the enzyme, fructosyltransferase, could be a fungus such as *Aspergillus niger*.

Richards (U.S. Patent No. 5,318,794) discloses a method for producing a product (caramel) containing between 20 and 50% fructooligosaccharides, having a degree of polymerization (DP) of about 3-10. The method comprises heating sucrose and an organic acid until fructose oligosaccharides are formed. This method produces a mixture of oligosaccharides, many of which differ in structure from the GF₂, GF₃ and GF₄ used in the present invention.

Richards et al. (WO 94/27618) discloses a method for the treatment and prevention of diarrhea comprising administration of a caramel prepared according to U.S. Patent No. 5,318,794 or U.S. Patent 5,206,355. These patents disclose a method for the preparation of trisaccharides and a fructoglucan sucrose polymer. WO 94/27618 provides examples of infants and adults suffering from diarrhea who were treated with the caramels. The present invention is, by contrast, directed to a method for decreasing the duration of diarrhea episodes by the administration of products containing the fructooligosaccharides GF₂, GF₃ and GF₄. WO 94/27618 claims a method for treatment or prevention of diarrhea, but only gives examples of treatment. The present invention relates to prophylactic use of FOS to shorten duration of diarrhea.

Analysis of human breast milk has determined that it does not contain the FOS useful in this invention. Kunz and Rudloff have reported in an article entitled "Biological Functions of Oligosaccharides in Human Milk", *Acta Paediatr.* 82:903-12 (1993) that the monomers of breast milk oligosaccharides are D-glucose, D-galactose, N-
5 acetylglucosamine, L-fucose and sialic acid. With few exceptions, all of the breast milk oligosaccharides carry lactose at their reducing end. In contrast, the present inventors have discovered that the very different fructooligosaccharides (FOS) with a degree of polymerization of from 2 to 20, can reduce the manifestation of diarrhea in a human consuming from 0.5 to 5 grams per day FOS.

10 FOS are not hydrolyzed in the small intestine by human digestive enzymes and thus reach the large intestine intact. There, many intestinal microorganisms utilize them. FOS can be utilized most efficiently by bifidobacteria, which are believed to be highly beneficial organisms (Hidaka, et al.), but cannot be utilized by certain undesirable, such as *E. coli* and putrefactive bacteria such as *Clostridium perfringens* or *Clostridium difficile*.

15 Carbohydrates which are not digested in the small intestine can be fermented to short chain fatty acids by the microorganisms found in the large intestine. The selective utilization by intestinal bacteria leads to an increase in the presence of bifidobacteria, the production of short chain fatty acids, lowered pH in the large intestine, and the suppression of undesirable microorganisms and the toxins they produce (Hidaka et al.).

20 Animal toxicology studies have shown no evidence of toxicity, mutagenicity, or carcinogenic effects due to FOS (Clevenger et al., "Toxicological evaluation of neosugar: genotoxicity, carcinogenicity, and chronic toxicity", *Journal of the American College of Toxicology* 7:643-662, 1988). FOS is used in Japan in many food products and has been added to infant formula (Fructooligosaccharide Information Package, Coors BioTech, Inc.
25 May 1990).

SUMMARY OF THE INVENTION

There is disclosed a method for reducing the duration of diarrhea and the number of recurrent episodes of diarrhea in a human, said method comprises enterally administering a

therapeutically effective amount of an indigestible oligosaccharide to said human prior to an incident of diarrhea.

More specifically, the method of the present invention is accomplished through the administration of at least one indigestible oligosaccharide selected from
5 fructooligosaccharide, fructosans, xylooligosaccharides and galactooligosaccharides. More preferably, the fructooligosaccharide is selected from 1-kestose, nystose and 1^F- β -fructofuranosyl nystose.

In the method of this invention, the indigestible oligosaccharide can be administered in the form of candy, chewing gum, tablets, lozenges or a nutritional product.
10 For the treatment of infants, the indigestible oligosaccharide may be incorporated into an infant formula. The present invention can also be accomplished through incorporating the oligosaccharides, useful in this method, in follow-on formula, toddler's beverages, yogurts, milks, fruit juice, fruit-based drinks, dietary supplements and the like. One aspect of this invention relates to the discovery that the indigestible oligosaccharide is
15 administered to a human at a rate between 0.5 grams per day and 5 grams per day prior to the onset of diarrhea. In a more preferred embodiment, the human consumes 1.0 to 4.0 grams per day and in yet a still more preferred embodiment, the human consumes 1.5 to 3.5 grams per day of FOS.

In order to demonstrate the present invention, a clinical study was undertaken
20 testing whether the enteral administration of FOS would reduce the incidence and/or duration of diarrhea.


A 16 week, controlled, randomized, blinded study was undertaken to determine if prophylactic feeding of fructooligosaccharides or indigestible oligosaccharides can reduce the incidence and shorten the duration of diarrhea in young children. Children between the
25 ages of 10 and 24 months were randomly assigned to receive either a milk-based beverage which served as a control, or the same beverage supplemented with FOS.

DETAILED DESCRIPTION OF THE INVENTION



As used herein and in the claims, "indigestible oligosaccharides" refers to carbohydrates with a degree of polymerization of from 2 to 20 (GF₂ - GF₂₀) and/or a

molecular weight less than about 3,600 that is resistant to endogenous digestion in the human upper digestive tract. These "indigestible oligosaccharides" are utilized as a substrate for fermentation by selected bacteria like lactobacilli and bifidobacteria species and other nonpathogenic bacteria that reside in the lower gastrointestinal tract. Indigestible oligosaccharides that may be employed in the invention may be prepared enzymatically, prepared by chemical means or extracted from natural products. As used herein and the claims, a therapeutically effective amount of the indigestible oligosaccharides can range from 0.5 - 5 grams per day.

Chemical structures of sucrose and some fructooligosaccharides useful in the practice of the present invention are shown below.



Sucrose

GF_nF_m

The general structural formula is shown as GF_n and the fructosan molecule is designated F_m . Any molecule depicted as GF_n or F_m can be used in the practice of the present invention provided that n and m are between 2 and 20. These include in the preferred embodiment 1-kestose (GF_2 in which one molecule of fructose is bound to sucrose),
 5 nystose (GF_3 in which two molecules of fructose are bound to sucrose), and 1^F- β -fructofuranosyl nystose (GF_4 in which three molecules of fructose are bound to sucrose). In other embodiments of the invention, indigestible oligosaccharides such as xylooligosaccharides and galactooligosaccharides having a degree of polymerization ranging from 2 to 20 are also useful. Xylooligosaccharides selected from the group
 10 consisting of xylobiose, xylotriose and xylotetrose are useful in this invention. Galactooligosaccharides [(Galactose)_N-Galactose-Glucose], where N can range from 1 to 10 are also useful in the present invention.

In general, the invention relates to a method of reducing the duration of diarrhea in a human, said method comprising enterally administering a therapeutically effective
 15 amount of an indigestible oligosaccharide to said human. The indigestible oligosaccharide is selected from the group consisting of fructooligosaccharides, fructosans, xylooligosaccharides and galactooligosaccharides having a DP of 2 to 20.

Methods and Materials

The indigestible oligosaccharides used in the clinical study were synthesized
 20 according to the method disclosed in U.S. Patent 4,681,771 to Adachi et al. The teachings of U.S. 4,681,771 are incorporated herein by reference. The process comprises reacting sucrose in the presence of a fructosyltransferase from *Aspergillus niger* to obtain GF_2 , GF_3 , and GF_4 .

The FOS used in the clinical study was obtained from Golden Technologies, Inc. of
 25 Westminster, CO. The Fructooligosaccharides Powder was Lot. No. 931115 and had the following chemical analysis:

30	Moisture (w/w%)	-	2.5
	Carbohydrate composition (% dry basis)		
	Glucose and Fructose	-	0.5

	Sucrose	-	3.5
	FOS	-	96.0
	GF ₂	-	41.3
	GF ₃	-	45.7
5	GF ₄	-	9.0

The Fructooligosaccharides Powder was a white powder with a granular size of less than 42 mesh. This FOS was used to prepare the milk-based fortified infant formula substantially in accordance with U.S. Patent 5,021,245, the teachings of which are herein incorporated by reference. More specifically, to produce a 5,700 lb. batch of the powdered Experimental formula, a mixture of 20 lbs. of lactose, 110 lbs. of sucrose and 166 lbs. of FOS were dissolved in water. This carbohydrate solution was then combined with the protein, minerals, oils and vitamins set forth in Table 1, heat processed, homogenized, spray dried, and packaged into containers.

Study Design

A controlled blinded, randomized 16 week study of healthy children attending day care centers was conducted. Children between the ages of 10 and 24 months were enrolled in the study. The children were randomly assigned to be fed either a milk-based infant formula, which served as a Control, or an Experimental milk-based beverage supplemented with fructooligosaccharides (FOS). The study beverages were fed *ad libitum* as the child's sole source of milk beverages.

Upon entering into the study, children were placed under active surveillance for diarrhea and other significant medical illnesses. Evaluations were made at study day 7, 28, 56, 84 and 112. Research nurses visited the participating day care centers each week to ensure study compliance and identify episodes of diarrhea.

The primary outcome variables included incidence and duration of all diarrhea episodes.

Study Diet

The study beverages were powdered products that were reconstituted with water at the point of consumption. The powdered Control and Experimental beverages were

reconstituted by mixing 135 grams of powdered nutritional with 1 liter of water. The beverages contained approximately 670 to 725 Kcal per liter. The powdered products were provided in clinically labeled 400 gram cans. The beverage was a modified, fortified milk-based drink with or without FOS that met the nutrient levels recommended by the

5 Committee on Nutrition of the American Academy of Pediatrics as required by the Infant Formula Act of 1980. The study beverage compositions are shown in Table 1. Both beverages provided 20 calories per fluid ounce when reconstituted with water. The average daily intake for children receiving Control beverage was 750 mL and for children receiving

Experimental beverage was 766 mL which resulted in consumption of approximately 2.6

10 grams of FOS per day.

TABLE 1
PRODUCT COMPOSITION
Approximate Composition of Study Beverage
With or Without Fructooligosaccharides (per liter)

<u>NUTRIENT</u>	<u>Experimental Study Beverage with Fructooligosaccharides</u>	<u>Control Study Beverage</u>
Protein, g	15.3	15.3
Fat, g	37.2	37.2
Carbohydrate, g	74.7	74.7
Linolenic Acid, mg.	6500	6500
Vitamin A, IU	2900	2900
Vitamin D, IU	440	440
Vitamin K, mcg	112	112
Thiamine (B ₁), mcg	239	239
Riboflavin (B ₂), mcg	1505	1505
Vitamin B ₁₂ , mcg	3.24	3.24
Niacin, mcg	9000	9000
Folic Acid (Folacin), mcg	155	155

Pantothenic Acid, mcg	4250	4250
Biotin, mcg	45.0	45.0
Vitamin C (Ascorbic Acid), mg	150	150
Choline, mg	156	156
Inositol, mg	38	38
Calcium, mg	975	975
Phosphorus, mg	650	650
Magnesium, mg	75	75
Iron, mg	13	13
Zinc, mg	8.5	8.5
Manganese, mcg	52	52
Copper, mcg	710	710
Sodium, mg	220	220
Iodine, mcg	46	46
Potassium, mg	840	840
Chloride, mg	620	620
Taurine, mg	57.5	57.5
Energy (Kcal)	684	684
β -Carotene, mcg	400	400
% Kcal from protein	8.95	8.95
Nucleotides, mg	72	72
FOS	3.5	0

Study Subjects and Entry Procedures

Upon enrollment, study subjects were placed under continuous, active surveillance for diarrhea and other illnesses.

5 An initial assessment was made of each child attending the day care center. The children were in apparent good health with no clinical evidence of chronic gastroenteritis or diarrhea within seven days prior to enrollment; had no significant chronic or severe

renal, liver or gastrointestinal tract function abnormalities; no history of aspiration pneumonia within 3 months prior to enrollment; and did not suffer from immune deficiency or receive immunosuppressive therapy. Children participating in another investigational drug study one month prior to enrollment were excluded from entering the study.

Children were prohibited from receiving human milk feedings for the duration of the study. All children had a history of ingesting whole cow's milk or cow's milk-based infant formula prior to enrollment and exhibited no symptoms of cow's milk allergy or cow's milk protein intolerance. Children were randomly assigned to receive the Control or the Experimental beverage.

Study Evaluations

Day care center records and clinic or physician visits were monitored for clinically significant illness: non-specific upper respiratory tract infections, bronchitis, bronchiolitis, bronchopneumonia, otitis media, diarrhea and other significant illnesses. Each subject was evaluated at entry, 7, 28, 56, 84 and 112 days (± 3 days).

Diarrheal Episodes

Children were placed on active surveillance for diarrhea at enrollment and were followed through the 16 week study or until study exit. Parents and day care center workers were instructed to notify the research staff when a subject developed diarrhea.

Diarrhea was defined as three watery or loose stools in a 24 hour period as determined by the parent, guardian, or day care center worker. Duration of diarrhea was the period in days from onset until the time of the last loose or watery stool. A diarrhea stool record was completed by the parent and day care center personnel. Diarrhea stool samples were collected for evaluation for rotavirus and other enteric pathogens and for *C. difficile* toxin. Specimens were collected within two (2) days of diarrhea onset. A recurrent episode of diarrhea is defined as diarrhea occurring at least 7 days after the end of a previous episode.

Statistical Methods

Duration of diarrhea was analyzed by the log rank test. For diarrhea duration outcomes, an analysis was performed for all episodes counted. In defining an episode of diarrhea, at least seven days must elapse between episodes of diarrhea or it is considered a single two-stage episode. The results are reported in Table 2.

Table 2
EPISODES OF DIARRHEA

	EXPERIMENTAL N = 132	CONTROL N = 135
NUMBER OF CHILDREN WITH DIARRHEA	40	45
REPEAT EPISODES OF DIARRHEA	3	11
TOTAL NUMBER OF DIARRHEA EPISODES	43	56

Duration of Diarrhea Episodes

The duration of diarrhea was determined by the number of days between first and last reported watery or loose stool. Repeat episodes and duration of diarrhea were shorter in subjects consuming Experimental. The mean duration of diarrhea was 3.91 days for children in the Experimental group and 4.88 days for children in the Control group. These data include duration of all diarrhea episodes occurring after eight days or more on the study regimen and meeting the protocol definition of three watery or loose stools in a twenty-four hour period. The difference in duration of diarrhea between the Experimental and Control groups is significant with a probability of $p = .036$ using a marginal approach to Cox regression for clustered data. Data are summarized in Table 3.

Table 3

DURATION OF DIARRHEA EPISODES

	Experimental	Control
NUMBER OF EPISODES	43	56
MEAN DURATION IN DAYS*	3.91	4.88

*p=.036

Repeat Episodes of Diarrhea

The number of repeat episodes of diarrhea was less in the Experimental than the Control group. These results indicate feeding FOS can decrease the number of recurrent episodes of diarrhea.

It is concluded from the results of the clinical study that administration of an indigestible oligosaccharide reduces the duration and number of recurrent episodes of diarrhea in children. Indigestible oligosaccharides, such as FOS, can be added to various nutritional products including but not limited to infant formula, milk-based and fruit-based products for older children and adults to accomplish the method of this invention. FOS may also be formulated in candies, lozenges, chewing gums, tablets and mixed into other food products.

Through the work of this investigation, it has been shown that the method of the present invention is efficacious and has been determined to be safe. The clinical trial proved the efficacy of the disclosed and claimed use of FOS in reducing the duration and recurrence of diarrhea. Differences were observed and support the present invention in

reducing the duration and recurrence of diarrhea in children when taken as part of the daily diet. The prior art does not suggest or disclose that the prophylactic, enteral administration of FOS would be effective in reducing the duration of diarrhea.

Industrial Applicability

5 The results from the clinical study demonstrate that the method of this invention is effective in reducing the duration and recurrence of diarrhea. The medical community is constantly searching for methods and products that will be useful in the management of diarrhea and the present invention supplies a new approach to the control of this common problem.

10 While the methods and products wherein described constituted a preferred embodiment of this invention, it is understood that the invention is not limited to the precise method or formulation and that changes may be made therein without departing from the scope of the invention which is defined in the appended claims.

What is claimed is:

1. A method of reducing the duration of diarrhea in a human, said method comprises enterally administering a therapeutically effective amount of an indigestible oligosaccharide to said human.
2. The method of claim 1 wherein the indigestible oligosaccharide is selected from the group consisting of fructooligosaccharides, fructosans, xylooligosaccharides and galactooligosaccharides.
3. The method of claim 2 wherein the indigestible oligosaccharide is selected from the group consisting of 1-kestose, nystose, and 1^F- β -fructofuranosyl nystose.
4. The method of claim 1 wherein the indigestible oligosaccharide is administered in a nutritional product.
5. The method of claim 4 wherein the nutritional product is an infant formula, follow-on formula, toddler's beverage, milk, yogurt, or fermented product.
6. The method of claim 4 wherein the nutritional product is a fruit juice, a fruit-based drink, or a dietary supplement.
7. The method of claim 1 wherein the indigestible oligosaccharide is administered in a candy, a chewing gum, a tablet, a lozenge or a liquid.
8. The method of claim 1 wherein the indigestible oligosaccharide is administered at a rate of at least 0.5 grams per day to 5 grams per day.

9. A method for the reduction of recurrent episodes of diarrhea in a human, said method comprises enterally administering a therapeutically effective amount of an indigestible oligosaccharide to said human.

10. The method of claim 9 wherein the indigestible oligosaccharide is selected from the group consisting of fructosans, xylooligosaccharides and galactooligosaccharides.

11. The method of claim 10 wherein the indigestible oligosaccharide is selected from the group consisting of 1-kestose, nystose, and 1^F- β -fructofuranosyl nystose.

12. The method of claim 9 wherein the indigestible oligosaccharide is administered in a nutritional product.

13. The method of claim 12 wherein the nutritional product is an infant formula, follow-on formula, toddler's beverage, milk, yogurt or fermented product.

14. A method according to claim 12 wherein the nutritional product is a fruit juice, a fruit based drink or a dietary supplement.

15. A method according to claim 9 wherein the indigestible oligosaccharide is administered in a candy, a tablet, a chewing gum, a lozenge or a liquid.

16. A method according to claim 9 wherein the indigestible oligosaccharide is administered at a rate of at least 0.5 grams per day to 5 grams per day.

17. A composition useful for reducing the duration and recurrence of diarrhea, said composition comprising at least one indigestible oligosaccharide selected from the group consisting of fructooligosaccharides, fructosans, xylooligosaccharides and galactooligosaccharides.

18. The composition according to claim 16 wherein the indigestible oligosaccharide is selected from the group consisting of 1-kestose, nystose and 1^F- β -fructofuranosyl nystose.

19. A method for reducing the duration of diarrhea in a human, said method comprises enterally administering to said human at least 0.5 grams per day of at least one fructooligosaccharide selected from the group consisting of GF₂, GF₃ and GF₄.

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 31/70, 31/715		A3	(11) International Publication Number: WO 97/02829
			(43) International Publication Date: 30 January 1997 (30.01.97)
(21) International Application Number: PCT/US96/11201		(81) Designated States: AU, BR, CA, IL, JP, MX, NO, NZ, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(22) International Filing Date: 2 July 1996 (02.07.96)			
(30) Priority Data: 60/001,036 11 July 1995 (11.07.95) US 08/653,084 11 June 1996 (11.06.96) US		Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(71) Applicant: ABBOTT LABORATORIES [US/US]; CHAD 377/AP6D-2, One Abbott Park Road, Abbott Park, IL 60064-3500 (US).		(88) Date of publication of the international search report: 27 March 1997 (27.03.97)	
(72) Inventors: DOHNALEK, Margaret, Ione, Halpin; 1483 Buck Trail Lane, Worthington, OH 43085 (US). OSTROM, Karin, Margaret; 7788 Quarry Cliff Court, Reynoldsburg, OH 43068 (US). HILTY, Milo, Duane; 9984 S. Old State Road, Lewis Center, OH 43035 (US).			
(74) Agents: BRAINARD, Thomas, D.; Abbott Laboratories, Ross Products Division, Dept. 108140 DS/1, 625 Cleveland Avenue, Columbus, OH 43215 (US) et al.			
(54) Title: USE OF INDIGESTIBLE OLIGOSACCHARIDES TO PREVENT AND TREAT DIARRHEA			
(57) Abstract <p>A method is provided for reducing the duration of diarrhea and recurrent episodes of diarrhea in humans by enterally administering indigestible oligosaccharides prophylactically. More specifically, the present invention relates to a method using indigestible oligosaccharides or fructooligosaccharides (FOS) to reduce the duration and recurrence of diarrhea in a human wherein between 0.5 grams and 5 grams of at least one FOS selected from the group consisting of 1-kestose, nystose, and 1F-β-fructofuranosyl nystose is administered to said human per day. The indigestible oligosaccharides can be produced through enzymatic synthesis, chemical techniques or isolated from plant materials and are administered in the form of a nutritional product, candy, tablets, chewing gum, lozenges, milk, yogurts, fermented products and the like.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LJ	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 96/11201

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K31/70 A61K31/715.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	US 5 444 054 A (GARLEB ET AL) 22 August 1995 see the whole document especially Claim 7 ---	1-19
X	WO 94 27618 A (UNIVERSITY OF MONTANA) 8 December 1994 cited in the application see the whole document ---	1-17
X	US 4 987 124 A (SPEIGHTS ET AL) 22 January 1991 see the whole document ---	1-17
	-/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- *A* document member of the same patent family

Date of the actual completion of the international search

14 February 1997

Date of mailing of the international search report

26.02.97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+ 31-70) 340-3016

Authorized officer

Mair, J

INTERNATIONAL SEARCH REPORT

Int. onal Application No
PCT/US 96/11201

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	PATENT ABSTRACTS OF JAPAN vol. 9, no. 287 (C-314), 14 November 1985 & JP 60 133852 A (ZENKOKU SHIYOKUBUTSU TANPAKU SHIYOKUHIN KIYODOUKUMIAI), 17 July 1985, see abstract ---	1-17
X	FASEB JOURNAL, vol. 9, no. 3, 1995, page A368 XP002025324 CHANDRA, G. ET AL: "The addition of neosugar to oral electrolyte solutions (OES) for treatment of acute diarrhea" see abstract ---	1-17
X	PATENT ABSTRACTS OF JAPAN vol. 17, no. 670 (C-1139), 9 December 1993 & JP 05 219897 A (AJINOMOTO CO INC), 31 August 1993, see abstract ---	1-17
X	DATABASE WPI Week 8915 Derwent Publications Ltd., London, GB; AN 89-109964 XP002025325 & JP 01 055 150 A (SUNTORY LTD.) , 2 March 1989 see abstract ---	1-17
X	EP 0 293 935 A (MITSUI TOATSU CHEMICALS INC) 7 December 1988 see the whole document ---	1-17
X	US 4 873 229 A (DEYA ET AL) 10 October 1989 see the whole document ---	1-17
X	EP 0 549 478 A (MATSUTANI CHEMICAL INDUSTRIES CO. LTD.) 30 June 1993 see the whole document -----	1-17

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 96/11201

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claim(s) 1-19
is(are) directed to a method of treatment of the human/animal
body, the search has been carried out and based on the alleged
effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 96/11201

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US-A-5444054	22-08-95	AU-A- 1884495 CA-A- 2187628 EP-A- 0754001 WO-A- 9526646	23-10-95 12-10-95 22-01-97 12-10-95
WO-A-9427618	08-12-94	US-A- 5439893 AU-A- 6946594	08-08-95 20-12-94
US-A-4987124	22-01-91	US-A- 4902674 AU-A- 6728690 EP-A- 0500688 WO-A- 9107181 US-A- 5032579 AT-T- 122888 AU-A- 2625588 CA-A- 1337045 DE-D- 3853888 DE-T- 3853888 EP-A- 0381700 JP-T- 3501971 WO-A- 8903218	20-02-90 13-06-91 02-09-92 30-05-91 16-07-91 15-06-95 02-05-89 19-09-95 29-06-95 02-11-95 16-08-90 09-05-91 20-04-89
EP-A-293935	07-12-88	DE-A- 3874613 JP-A- 1252257 US-A- 4865852 US-A- 4971815	22-10-92 06-10-89 12-09-89 20-11-90
US-A-4873229	10-10-89	JP-C- 1685936 JP-B- 2057902 JP-A- 62138147 FR-A- 2591484	11-08-92 06-12-90 20-06-87 19-06-87
EP-A-549478	30-06-93	AU-B- 659896 AU-A- 3029492 JP-A- 5244878 NZ-A- 245559	01-06-95 01-07-93 24-09-93 27-06-95